Diane Bohn, MS, RN, ANP-BC
Articles
Staffing and Scheduling for Subcutaneous
Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot strategies—combined with strong leadership and patient education—to enhance efficiency, staff engagement, and the overall care experience.
Operational Shifts: IV to Subcutaneous
Panelists discuss how integrating subcutaneous (SubQ) therapies into oncology practice involves thorough economic evaluation, coordinated team education, patient engagement, and workflow adjustments to ensure financial viability, clinical effectiveness, and enhanced patient satisfaction.
Implementing Subcutaneous Without Disruption
Panelists discuss how successfully integrating subcutaneous (SubQ) therapies into oncology practice depends on comprehensive education, optimized workflows, transparent patient communication, and ongoing evaluation to ensure improved care quality and operational efficiency.
Reimbursement Realities: Billing for Subcutaneous
Panelists discuss how incorporating subcutaneous (SubQ) formulations into clinical formularies requires careful evaluation of clinical equivalence, workflow fit, and reimbursement logistics, with pharmacy and therapeutics committees balancing patient benefit, operational feasibility, and financial risk to guide adoption.
Workflow Wins: Scheduling and Pharmacy Impact
Panelists discuss how subcutaneous (SubQ) oncology treatments are reshaping clinic operations by improving infusion chair utilization, enabling flexible scheduling, streamlining pharmacy workflows, and prompting new care delivery models that enhance both efficiency and patient experience.
Subcutaneous Value: Efficiency and Access
Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ultimately supporting a more scalable and sustainable care model.
The Shifting to Subcutaneous Oncology: Recent FDA Approvals
Panelists discuss how the shift from intravenous (IV) to subcutaneous (SubQ) drug administration is transforming oncology care delivery, highlighting its lasting impact on patient experience, health care efficiency, and clinical workflows in light of recent FDA approvals and evolving pharmaceutical strategies.
